FY2025 Earnings Forecast for AbbVie Issued By Zacks Research

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Zacks Research dropped their FY2025 earnings estimates for AbbVie in a research report issued on Wednesday, January 14th. Zacks Research analyst Team now forecasts that the company will post earnings of $9.94 per share for the year, down from their prior estimate of $10.64. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q4 2025 earnings at $2.65 EPS, Q4 2026 earnings at $3.69 EPS and Q4 2027 earnings at $4.15 EPS.

ABBV has been the topic of several other research reports. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Evercore ISI raised their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Guggenheim lifted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, Morgan Stanley increased their target price on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $247.84.

AbbVie Stock Performance

NYSE:ABBV opened at $214.38 on Monday. The company has a market capitalization of $378.89 billion, a price-to-earnings ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie has a one year low of $164.39 and a one year high of $244.81. The stock has a 50-day simple moving average of $226.80 and a 200 day simple moving average of $216.65.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

Institutional Trading of AbbVie

A number of large investors have recently modified their holdings of ABBV. Norges Bank bought a new stake in shares of AbbVie during the second quarter valued at approximately $4,288,200,000. Wellington Management Group LLP increased its position in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the period. Laurel Wealth Advisors LLC increased its position in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after acquiring an additional 5,675,095 shares during the period. Vanguard Group Inc. raised its stake in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in AbbVie by 169.3% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after acquiring an additional 2,969,202 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.